Back to top
more

Penumbra (PEN)

(Delayed Data from NYSE)

$233.30 USD

233.30
525,994

+4.43 (1.94%)

Updated Nov 1, 2024 04:00 PM ET

After-Market: $233.26 -0.04 (-0.02%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value A Growth A Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 32% (79 out of 250)

Industry: Medical - Instruments

Better trading starts here.

Zacks News

Here's Why You Should Retain Bruker (BRKR) Stock for Now

Investors continue to be optimistic about Bruker Corporation (BRKR) based on the strong performances of CALID and BioSpin Group and its raised 2023 outlook.

Boston Scientific (BSX) Gains From Acquisitions, New Launches

Boston Scientific (BSX) remains excited about 2023 performance and expects to continue to outpace its peers within the EMEA market.

Abbott (ABT) Unveils Late-Breaking Data on Leadless Pacemaker

Abbott (ABT) study analyzes primary safety and efficacy endpoints in the first 300 people enrolled across 55 centers in the United States, Canada and Europe.

Medtronic's (MDT) EV ICD Pivotal Study Shows Favorable Outcome

Medtronic (MDT) announces that the findings of the EV ICD Pivotal Study reinforce device safety and effectiveness.

Here's Why You Should Retain Chemed (CHE) Stock for Now

Investors continue to be optimistic about Chemed (CHE) on the strong performance of the VITAS Healthcare and Roto-Rooter segments.

Exact Sciences (EXAS) Gains From New Buyouts Amid High Costs

Following the acquisitions of Paradigm and Ashion, Exact Sciences (EXAS) is now offering therapy selection tests for patients with advanced cancer.

Here's Why You Should Retain Insulet (PODD) Stock for Now

Investors continue to be optimistic about Insulet (PODD) on the robust performance of Omnipod 5.

Zacks.com featured highlights Penumbra, Lamb Weston, Transportadora de Gas del Sur and AeroVironment

Penumbra, Lamb Weston, Transportadora de Gas del Sur and AeroVironment have been highlighted in this Screen of The Week article.

Thermo Fisher (TMO) Gets FDA Clearance for Its Immunoassays

Thermo Fisher (TMO) announces the FDA clearance of its blood-based biomarkers used in the determination of risk assessment and clinical management of preeclampsia with severe features.

Nilanjan Banerjee headshot

Buy These 4 Low-Beta Stocks to Sail Through Market Volatility

It is imperative to build a portfolio of low-beta stocks to sail through a choppy market. Penumbra (PEN), Lamb Weston (LW), Transportadora (TGS) and AeroVironment (AVAV) are poised to gain.

Here's Why You Should Retain QIAGEN (QGEN) Stock for Now

QIAGEN (QGEN) is likely to benefit from high organic growth across its non-COVID-19 product group and portfolio advancements, reflecting a positive share price movement.

Here's Why You Should Retain Myriad Genetics (MYGN) Stock Now

Myriad Genetics (MYGN) is likely to benefit from testing volumes across product segments and the latest partnerships, reflecting a positive share price movement.

Illumina (ILMN) Progresses in Pathogen Genomic Technologies

Illumina's (ILMN) genomic surveillance solutions enable better pathogen preparedness and response.

Hologic (HOLX) Announces Collaboration With NFL CB Kelee Ringo

Hologic (HOLX) and Eagles' CB, Kelee Ringo, come together to highlight the importance of annual mammograms and other routine health screenings.

Here's Why You Should Retain Charles River (CRL) Stock Now

Charles River's (CRL) share price is likely to grow, backed by strategic acquisitions and the DSA segment's strength.

LabCorp (LH) Base Business Growth Strong, Margin Pressure Stays

LabCorp (LH) is progressing well with its planned spin-off of the Clinical Development business, which is expected to be completed in mid-2023.

Here's Why Investors Should Retain Henry Schein (HSIC) for Now

Henry Schein (HSIC) is expected to witness a favorable share price movement, led by optimism surrounding the performance of the dental business and strategic buyouts.

Integra (IART) Builds Advanced R&D Facility in New Jersey

Integra (IART) opens the Dr. Richard E. Caruso Center of Innovation and Learning in New Jersey.

Syneos Health (SYNH) Announces a $7.1 Billion Merger Agreement

Syneos Health (SYNH) is set to become private company following a $7.1 billion merger deal to be acquired by a private investment consortium.

Walgreens Boots (WBA) New Alliances Aid Growth, Cost Woe Stays

Intensifying competition in the U.S. pharmacy retail drugstore market compels Walgreens Boots (WBA) to diversify its product offerings through new partnerships.

Penumbra (PEN) Hits 52-Week High: What's Driving the Rise?

Penumbra (PEN) outperforms the industry and the S&P 500, backed by investors' optimism about the recently released first-quarter 2023 results.

Thermo Fisher (TMO) Partners With Pfizer to Expand NGS Testing

Thermo Fisher's (TMO) latest collaboration with Pfizer is set to enhance localized access to NGS-based testing capabilities for breast and lung cancer across international markets.

Zacks.com featured highlights include Penumbra, Lamb Weston, Transportadora de Gas del Sur and Novo Nordisk

Penumbra, Lamb Weston, Transportadora de Gas del Sur and Novo Nordisk are part of the Zacks Screen of the Week article.

Nilanjan Banerjee headshot

Buy These 4 Low-Beta Stocks to Endure Market Volatility

It is imperative to build a portfolio of low-beta stocks to sail through a choppy market. Penumbra (PEN), Lamb Weston (LW), Transportadora (TGS) and Novo Nordisk (NVO) are poised to gain.